TY - JOUR AU - Pavlovsky, Astrid PY - 2019 TI - Better understanding and new challenges in high grade lymphomas JF - Annals of Lymphoma; Vol 3 (December 2019): Annals of Lymphoma Y2 - 2019 KW - N2 - Diffuse large B-cell lymphoma (DLBCL), comprise the most commonly diagnosed non-Hodgkin lymphoma. Approximately 60–65% of patients can be cured with standard front-line therapy R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). However, the progress in the understanding of the disease has led us to appreciate its underlying heterogeneity. UR - https://aol.amegroups.org/article/view/5567